Board Change • Jul 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Jun 30
Third quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.002 loss in 3Q 2021) Third quarter 2022 results: CA$0.006 loss per share (down from CA$0.002 loss in 3Q 2021). Net loss: CA$560.9k (loss widened 269% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Board Change • Jun 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • May 26
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • May 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Apr 02
Second quarter 2022 earnings released: EPS: CA$0.021 (vs CA$0.002 loss in 2Q 2021) Second quarter 2022 results: EPS: CA$0.021 (up from CA$0.002 loss in 2Q 2021). Revenue: CA$235.4k (down 33% from 2Q 2021). Net income: CA$2.09m (up CA$2.30m from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Reported Earnings • Dec 05
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: CA$0.017 loss per share (down from CA$0.014 loss in FY 2020). Revenue: CA$1.06m (up 15% from FY 2020). Net loss: CA$1.61m (loss widened 42% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings. Reported Earnings • Jul 01
Third quarter 2021 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: CA$311.0k (up 124% from 3Q 2020). Net loss: CA$151.9k (loss narrowed 60% from 3Q 2020). Reported Earnings • Jan 16
First quarter 2021 earnings released: CA$0.003 loss per share The company reported a soft first quarter result with weaker revenues and control over expenses, though losses reduced. First quarter 2021 results: Revenue: CA$172.2k (down 56% from 1Q 2020). Net loss: CA$311.4k (loss narrowed 27% from 1Q 2020). 공시 • Jan 08
Eastwest Bioscience Inc. Announces Executive Changes Eastwest Bioscience Inc. announced that the Corporation has appointed Ciska Asriel to serve as interim Chief Financial Officer, in addition to her regular duties as Chief Operating Officer. Ms. Asriel will replace Paul Marjerrison as Chief Financial Officer and the Corporation would like to thank Mr. Marjerrison for his dedicated service. Ciska Asriel is the current Chief Operating Officer of the Corporation. Before joining EastWest as a Co-Founder and Chief Operating Officer, Ms. Asriel worked as a consultant, senior analyst and project manager for small companies as well as major firms including Deloitte. Her career experience is with project management, data analysis and business development in industry sectors including information technology, retail franchise operations, automotive franchise operations and insurance, global shipping and most recently software engineering and the development of mobile applications. Ms. Asriel's appointment is subject to approval by the TSX Venture Exchange. Reported Earnings • Dec 31
Full year 2020 earnings released: CA$0.014 loss per share The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: CA$922.8k (down 34% from FY 2019). Net loss: CA$1.13m (loss narrowed 69% from FY 2019). 공시 • Jul 30
EastWest Bioscience Inc. (TSXV:EAST) completed the acquisition of remaining 50% stake in 1123573 BC Ltd. and Orchard Valley Naturals Ltd. from Darryl Sangster, Aquila Health Corp. and Sangster's Real Estate Corp. EastWest Bioscience Inc. (TSXV:EAST) agreed to acquire remaining 50% stake in 1123573 BC Ltd. and Orchard Valley Naturals Ltd. from Darryl Sangster, Aquila Health Corp. and Sangster's Real Estate Corp. for CAD 0.08 million on December 18, 2019. Under the terms of the agreement, EastWest Bioscience Inc. will pay 2.77 million shares as consideration. EastWest Bioscience Inc. already hold 50% stake in 1123573 BC Ltd. and Orchard Valley Naturals Ltd. Post acquisition, EastWest Bioscience Inc. will hold 100% stake in 1123573 BC Ltd. and Orchard Valley Naturals Ltd. The transaction is subject to approval of the TSX Venture Exchange.
EastWest Bioscience Inc. (TSXV:EAST) completed the acquisition of remaining 50% stake in 1123573 BC Ltd. and Orchard Valley Naturals Ltd. from Darryl Sangster, Aquila Health Corp. and Sangster's Real Estate Corp. on February 11, 2020. 공시 • Jun 19
EastWest Bioscience Inc. announced that it expects to receive CAD 0.1 million in funding EastWest Bioscience Inc. (TSXV:EAST) announced a private placement of up to 2,000,000 common shares at an issue price of CAD 0.05 per share for gross proceeds of up to CAD 100,000 on June 18, 2020. All securities issued in the transaction have a hold period of 4 months. The transaction is subject to approval from TSX Venture Exchange. 